Alnylam Pharmaceuticals
ALNY
#637
Rank
NZ$51.15 B
Marketcap
$395.23
Share price
1.76%
Change (1 day)
60.82%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.55

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$6.93. In 2022 the company made an earnings per share (EPS) of -$15.65 a decrease over its 2021 EPS that were of -$12.13.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.55-58.13%
2022-$15.6529.03%
2021-$12.13-3.36%
2020-$12.55-8.48%
2019-$13.727.67%
2018-$12.7439.74%
2017-$9.1212.94%
2016-$8.0738.84%
2015-$5.81-32.88%
2014-$8.66259.44%
2013-$2.41-31.25%
2012-$3.5052.94%
2011-$2.2930.77%
2010-$1.75-8.77%
2009-$1.9278.13%
2008-$1.08-70.78%
2007-$3.6999.09%
2006-$1.85-43.88%
2005-$3.30-82.33%
2004-$18.69-59.23%
2003-$45.85

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.86-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$62.95-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.19 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.45-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.85-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.30-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$5.36-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.37-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel